Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy()

BACKGROUND: Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5–10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the impact of temporary ET interruption to allow pregnancy....

Descripción completa

Detalles Bibliográficos
Autores principales: Partridge, Ann H., Niman, Samuel M., Ruggeri, Monica, Peccatori, Fedro A., Azim, Hatem A., Colleoni, Marco, Saura, Cristina, Shimizu, Chikako, Sætersdal, Anna Barbro, Kroep, Judith R., Mailliez, Audrey, Warner, Ellen, Borges, Virginia F., Amant, Frédéric, Gombos, Andrea, Kataoka, Akemi, Rousset-Jablonski, Christine, Borstnar, Simona, Takei, Junko, Lee, Jeong Eon, Walshe, Janice M., Borrego, Manuel Ruíz, Moore, Halle CF., Saunders, Christobel, Cardoso, Fatima, Susnjar, Snezana, Bjelic-Radisic, Vesna, Smith, Karen L., Piccart, Martine, Korde, Larissa A., Goldhirsch, Aron, Gelber, Richard D., Pagani, Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365381/
https://www.ncbi.nlm.nih.gov/pubmed/34390999
http://dx.doi.org/10.1016/j.breast.2021.07.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365381/
https://www.ncbi.nlm.nih.gov/pubmed/34390999
http://dx.doi.org/10.1016/j.breast.2021.07.021

Ejemplares similares